CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

On August 29, 2019, Catalyst Biosciences, Inc. (the “Company”) announced that Fletcher Payne has voluntarily resigned from his position as the Company’s Chief Financial Officer to pursue another opportunity, effective as of August 30, 2019 (the “Effective Date”). The Company is initiating a replacement search for its next chief financial officer and Mr. Payne has agreed to provide consulting services following the Effective Date to provide advice regarding the transition of responsibilities.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1    Press release dated August 29, 2019 and titled “Catalyst Biosciences Announces Transition of Chief Financial Officer.”


CATALYST BIOSCIENCES, INC. Exhibit
EX-99.1 2 d18370dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Biosciences Announces Transition of Chief Financial Officer SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.